金斯瑞生物科技(01548.HK):金斯康香港與鎮江新區訂立投資協議以擴大分子生物研發項目規模
格隆匯12月30日丨金斯瑞生物科技(01548.HK)公佈,於12月26日,其間接全資附屬公司金斯康(香港)有限公司與鎮江新區管理委員會訂立投資協議,內容有關租賃三間工廠,以擴大於中國鎮江經濟技術開發區的分子生物研發項目的規模。
公告顯示,項目公司的註冊資本將增加一千萬美元。金斯康香港透過其直接全資附屬公司江蘇金斯瑞生物科技有限公司將以固定資產及現金出資的形式投資總計人民幣1.8億元,用於建設工廠、辦公大樓及其他倉儲設施,以擴大(i)分子生物產能,(ii)細胞治療載體質粒技術的研究實驗室及(iii)多肽GMP業務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.